| Description | MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). |
| Target activity | IP receptor (human):20 nM(Ki) |
| Synonyms | 3-氧代-12-烯-28-乌苏酸, MRE 269, ACT-333679, MRE269 |
| molecular weight | 419.52 |
| Molecular formula | C25H29N3O3 |
| CAS | 475085-57-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (131.1 mM) |
| References | 1. Kuwano, K., et al.: J. Pharmacol. Exp. Ther., 322, 1181-1188 (2007) 2. Skoro-Sajer, N., et al.: Expert. Opin. Pharmaco., 15, 429-436 (2014) 3. Sitbon, O., et al.: Eur. Resp. Rev., 21, 321 (2012) |